2022 ESC Guidelines on cardio-oncology
The first ESC cardio-oncology guideline builds a full pathway: baseline cardiovascular risk stratification before cancer therapy, surveillance during it, and management of cancer-therapy-related cardiac dysfunction afterwards. The randomised cardioprotection evidence is small and rests on imaging surrogates rather than hard outcomes — a limitation the guideline states openly. The register's trials are grouped by protective strategy below.
This guideline cites 3 of the 199 landmark trials in our Cardiology register.
Neurohormonal cardioprotection3
- 2017MANTICORE 101-BreastCardiology · Cardioprotection · HER2 cardiotoxicityMultidisciplinary Approach to Novel Therapies in Cardio-Oncology Research 101-Breast
- 2016PRADACardiology · Cardioprotection · Anthracycline cardiotoxicityPRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy
- 2013OVERCOMECardiology · Cardioprotection · Neurohormonal prophylaxisPreventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies
Published since the guideline2
- 2025SAFECardiology · Cardioprotection · Anthracycline cardiotoxicityCardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab (SAFE trial)
- 2023STOP-CACardiology · Cardioprotection · Statin cardioprotectionStatins TO Prevent the Cardiotoxicity From Anthracyclines